Factors associated with adherence to BRCA1/2 mutation testing after oncogenetic counseling in long-surviving patients with a previous diagnosis of breast or ovarian cancer.

Autor: Actis S; Gynecology and Obstetrics Unit, Mauriziano Umberto I Hospital, Department of Surgical Sciences, University of Turin, Largo Filippo Turati, 62, 10128, Turin, Italy. silvia.actis@unito.it., D'Alonzo M; Gynecology and Obstetrics Unit, Mauriziano Umberto I Hospital, Department of Surgical Sciences, University of Turin, Largo Filippo Turati, 62, 10128, Turin, Italy., Pace L; Gynecology and Obstetrics Unit, Mauriziano Umberto I Hospital, Department of Surgical Sciences, University of Turin, Largo Filippo Turati, 62, 10128, Turin, Italy., Mucciacito S; Gynecology and Obstetrics Unit, Mauriziano Umberto I Hospital, Department of Surgical Sciences, University of Turin, Largo Filippo Turati, 62, 10128, Turin, Italy., Bounous VE; Gynecology and Obstetrics Unit, Mauriziano Umberto I Hospital, Department of Surgical Sciences, University of Turin, Largo Filippo Turati, 62, 10128, Turin, Italy., Sgrò LG; Gynecology and Obstetrics Unit, Mauriziano Umberto I Hospital, 10128, Turin, Italy., Mancarella M; Gynecology and Obstetrics Unit, Mauriziano Umberto I Hospital, 10128, Turin, Italy., Ferrero A; Gynecology and Obstetrics Unit, Mauriziano Umberto I Hospital, Department of Surgical Sciences, University of Turin, Largo Filippo Turati, 62, 10128, Turin, Italy., Biglia N; Gynecology and Obstetrics Unit, Mauriziano Umberto I Hospital, Department of Surgical Sciences, University of Turin, Largo Filippo Turati, 62, 10128, Turin, Italy.
Jazyk: angličtina
Zdroj: Journal of community genetics [J Community Genet] 2023 Dec; Vol. 14 (6), pp. 649-656. Date of Electronic Publication: 2023 Sep 19.
DOI: 10.1007/s12687-023-00671-x
Abstrakt: BRCA1/2 mutations account for 5 to 10% of breast and 15% of ovarian cancers. Various guidelines on BRCA1/2 genetic counseling and testing have been issued, and the criteria have evolved over the years. Oncogenetic counseling aims to inform patients about the possibility and implications of undergoing predictive testing and risk management programs. We analyzed a cohort of 50 subjects with a previous personal history of breast or ovarian cancer who had not been tested for BRCA1/2 mutations at the time of diagnosis but were found eligible according to the most recent guidelines. All patients were offered pre-test oncogenetic counseling and BRCA1/2 genetic testing. The mean time from cancer diagnosis to genetic counseling was over 10 years. We analyzed socio-demographic and psychological parameters associated with the decision to undergo BRCA1/2 genetic testing or the reasons behind the withdrawal. Thirty-nine patients underwent BRCA1/2 genetic testing. Patients who accept the genetic test communicate more easily with family members than those who refuse. Factors associated with test refusal are having a long-term partner and having a negative perception of life. There is a trend, although not statistically significant, toward younger age at cancer diagnosis, more likely to participate in cancer screening programs (71.8% vs. 45.5%), and more likely to have daughters (63.3% vs. 37.5%) in the group that accepted the test. The offer of BRCA testing was well accepted by our study population, despite the many years since the cancer diagnosis. With the perspective of further broadening the access criteria to genetic testing, it is important to understand how to best approach pre-test counseling in long-surviving patients with a previous diagnosis of cancer.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: